Medallion Financial (NASDAQ:MFIN) versus Advanced Medical Isotope (OTCMKTS:RDGL) Head-To-Head Contrast

Medallion Financial (NASDAQ:MFIN) and Advanced Medical Isotope (OTCMKTS:RDGL) are both small-cap finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership and valuation.

Risk and Volatility

Medallion Financial has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.77, indicating that its share price is 177% less volatile than the S&P 500.

Profitability

This table compares Medallion Financial and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medallion Financial	10.35%	7.73%	1.35%
Advanced Medical Isotope	-4,380.77%	N/A	-147.73%

Insider and Institutional Ownership

40.6% of Medallion Financial shares are owned by institutional investors. 24.6% of Medallion Financial shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Medallion Financial and Advanced Medical Isotope, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medallion Financial	0	2	1	0	2.33
Advanced Medical Isotope	0	0	0	0	0.00

Medallion Financial presently has a consensus price target of $12.00, indicating a potential upside of 25.92%. Given Medallion Financial’s stronger consensus rating and higher probable upside, research analysts clearly believe Medallion Financial is more favorable than Advanced Medical Isotope.

Earnings and Valuation

This table compares Medallion Financial and Advanced Medical Isotope”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medallion Financial	$353.31 million	0.64	$43.04 million	$1.48	6.44
Advanced Medical Isotope	$70,000.00	478.13	-$3.07 million	($0.01)	-6.78

Medallion Financial has higher revenue and earnings than Advanced Medical Isotope. Advanced Medical Isotope is trading at a lower price-to-earnings ratio than Medallion Financial, indicating that it is currently the more affordable of the two stocks.

Summary

Medallion Financial beats Advanced Medical Isotope on 13 of the 14 factors compared between the two stocks.

About Medallion Financial

Medallion Financial Corp., together with its subsidiaries, operates as a specialty finance company in the United States. It operates in four segments: Recreation Lending, Home Improvement Lending, Commercial Lending, and Taxi Medallion Lending. The company offers loans that finance consumer purchases of recreational vehicles, boats, and other consumer recreational equipment; consumer financing for window, siding, and roof replacement, swimming pool installations, and other home improvement projects; senior and subordinated loans for the purchase of equipment and related assets necessary to open a new business, or purchase or improvement of an existing business; and taxi medallion loans to individuals and small to mid-size businesses. It also provides debt, mezzanine, and equity investment capital to companies in various commercial industries; and raises deposits and conducts other banking activities. Medallion Financial Corp. was incorporated in 1995 and is headquartered in New York City, New York.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.